Gilteritinib
Gilteritinib
Gilteritinib (pronounced as gil-te-ri-ti-nib) is a type of medication used in the treatment of acute myeloid leukemia (AML). It is classified as a kinase inhibitor, specifically targeting the FMS-like tyrosine kinase 3 (FLT3) and AXL receptor tyrosine kinase (AXL).
Etymology
The name "Gilteritinib" is derived from the combination of parts of the words "Gilt", "Eri", and "Tinib". "Tinib" is a common suffix for kinase inhibitors. The origin of "Gilt" and "Eri" is not clearly known.
Usage
Gilteritinib is used for the treatment of adults who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. It works by blocking the action of the abnormal protein that signals cancer cells to multiply, helping to slow down or stop the spread of cancer cells.
Related Terms
- Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow.
- Kinase Inhibitor: A type of drug that blocks certain proteins called kinases.
- FMS-like tyrosine kinase 3 (FLT3): A protein that is often mutated in AML, leading to the rapid growth of cancer cells.
- AXL receptor tyrosine kinase (AXL): Another protein that is often overactive in cancer cells.
Side Effects
Common side effects of Gilteritinib include changes in liver function, joint pain, fatigue, fever, and shortness of breath. It can also cause more serious side effects, such as pancreatitis and differentiation syndrome.
See Also
External links
- Medical encyclopedia article on Gilteritinib
- Wikipedia's article - Gilteritinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski